The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice
- PMID: 15027488
The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice
Abstract
CD25+ regulatory T cells comprise 5-10% of CD4+ T cells in naïve mice and have been shown in several in vivo murine models to prevent the induction of autoimmune disease and inflammatory disease. Since T cells, which mediate autoimmunity, can through recognition of self-antigens also target tumour cells, it was postulated that CD25+ regulatory cells would also inhibit the generation of immune responses to rumours. Depletion of these cells using CD25-specific monoclonal antibodies has indeed been shown to promote rejection of several transplantable murine tumour cell lines including melanoma, leukaemia and colorectal carcinoma. Results obtained using these models indicate that in the absence of regulatory cells, CD4+ T cells mediate tumour immunity, although the precise mechanisms through which these cells result in tumour rejection have not yet been elucidated. The target antigens recognized by these CD4+ T cells have also not yet been identified. Immunization of mice with tumour cells in the absence of CD25+ regulatory cells does, however, induce immunity against a variety of different tumour cell lines indicating that the target antigen(s) are shared amongst tumours of distinct histological origins. Since CD25+ regulatory cells have been identified in humans, the possibility that the cells inhibit immune responses to shared rejection antigens expressed by human tumours is worthy of investigation.
Similar articles
-
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens.Eur J Immunol. 2002 Nov;32(11):3267-75. doi: 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1. Eur J Immunol. 2002. PMID: 12555672
-
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.Cancer Immun. 2002 Feb 22;2:1. Cancer Immun. 2002. PMID: 12747746
-
In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.Exp Dermatol. 2004 Oct;13(10):613-20. doi: 10.1111/j.0906-6705.2004.00198.x. Exp Dermatol. 2004. PMID: 15447721
-
CD25+ regulatory T cells and tumor immunity.Immunol Lett. 2003 Jan 22;85(2):141-3. doi: 10.1016/s0165-2478(02)00240-7. Immunol Lett. 2003. PMID: 12527220 Review.
-
The role of suppressor T cells in regulation of immune responses.J Allergy Clin Immunol. 2002 Nov;110(5):693-702. doi: 10.1067/mai.2002.129339. J Allergy Clin Immunol. 2002. PMID: 12417876 Review.
Cited by
-
Modulation of bone morphogenic protein signaling in T-cells for cancer immunotherapy.J Immunotoxicol. 2014 Oct;11(4):319-27. doi: 10.3109/1547691X.2013.864736. Epub 2013 Dec 19. J Immunotoxicol. 2014. PMID: 24350726 Free PMC article.
-
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.J Immunother Cancer. 2014 Oct 14;2(1):34. doi: 10.1186/s40425-014-0034-0. eCollection 2014. J Immunother Cancer. 2014. PMID: 25328681 Free PMC article.
-
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.J Immunother. 2006 Mar-Apr;29(2):208-14. doi: 10.1097/01.cji.0000187959.45803.0c. J Immunother. 2006. PMID: 16531821 Free PMC article.
-
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.Cancer Immunol Immunother. 2012 Jan;61(1):19-29. doi: 10.1007/s00262-011-1077-4. Epub 2011 Aug 7. Cancer Immunol Immunother. 2012. PMID: 21822917 Free PMC article.
-
A Flow Cytometry-Based Examination of the Mouse White Blood Cell Differential in the Context of Age and Sex.Cells. 2024 Sep 20;13(18):1583. doi: 10.3390/cells13181583. Cells. 2024. PMID: 39329764 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials